当前位置: 首页 >> 检索结果
121. Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, controlled, phase 3, non-inferiority trial.
作者: Fatoumata Diallo.;Fadima C Haidara.;Milagritos D Tapia.;Clara P Dominguez Islas.;Mark R Alderson.;William P Hausdorff.;Lionel Martellet.;Nancy Hosken.;Dhananjay Kapse.;Prasad S Kulkarni.;Kelly Townsend-Payne.;Francesca Vanni.;Christine M Posavad.;Samba O Sow.;Karen L Kotloff.;Wilbur H Chen.; .
来源: Lancet. 2025年405卷10484期1069-1080页
Invasive meningococcal disease is a devastating public health problem for the African meningitis belt. We assessed the safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, Y, W, and X (NmCV-5) relative to a licensed, quadrivalent meningococcal conjugate vaccine (MenACWY-TT) when co-administered with routine childhood vaccines at ages 9 months and 15 months.
122. Effect of digital adherence technologies on treatment outcomes in people with drug-susceptible tuberculosis: four pragmatic, cluster-randomised trials.
作者: Degu Jerene.;Kristian van Kalmthout.;Jens Levy.;Jason Alacapa.;Natasha Deyanova.;Tanyaradzwa Dube.;Andrew Mganga.;Bianca Tasca.;Alexsey Bogdanov.;Egwuma Efo.;Katya Gamazina.;Anna Marie Celina Garfin.;Volodymyr Kochanov.;Adrian Leung.;Norma Madden.;Noriah Maraba.;Christopher Finn McQuaid.;Liberate Mleoh.;Baraka Onjare.;Rachel Powers.;Yana Terleiva.;Job van Rest.;Agnes Gebhard.;Katherine Fielding.;Salome Charalambous.
来源: Lancet. 2025年405卷10485期1155-1166页
The impact of digital adherence technologies on tuberculosis treatment outcomes remains poorly understood. We investigated whether smart pillboxes and medication labels can reduce poor treatment outcomes in patients with tuberculosis.
123. Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
作者: Anwen Xiong.;Lei Wang.;Jianhua Chen.;Lin Wu.;Baogang Liu.;Jun Yao.;Hua Zhong.;Jie Li.;Ying Cheng.;Yulan Sun.;Hui Ge.;Jifang Yao.;Qin Shi.;Ming Zhou.;Bolin Chen.;Zhengxiang Han.;Jinliang Wang.;Qing Bu.;Yanqiu Zhao.;Junqiang Chen.;Ligong Nie.;Gaofeng Li.;Xingya Li.;Xinmin Yu.;Yinghua Ji.;Daqiang Sun.;Xiaohong Ai.;Qian Chu.;Yu Lin.;Jiqing Hao.;Dingzhi Huang.;Chengzhi Zhou.;Jinlu Shan.;Hongzhong Yang.;Xuewen Liu.;Jing Wang.;Yanhong Shang.;Xiaodong Mei.;Jie Yang.;Dongmei Lu.;Mingxiu Hu.;Zhongmin Maxwell Wang.;Baiyong Li.;Michelle Xia.;Caicun Zhou.
来源: Lancet. 2025年405卷10481期839-849页
Ivonescimab is a bispecific antibody against programmed cell death protein 1 and vascular endothelial growth factor, yielding promising clinical outcomes for patients with advanced non-small cell lung cancer in early-phase studies. We compared the efficacy and safety of ivonescimab with pembrolizumab in patients with programmed cell death ligand-1 (PD-L1)-positive advanced non-small cell lung cancer.
124. Atosiban versus placebo for threatened preterm birth (APOSTEL 8): a multicentre, randomised controlled trial.
作者: Larissa I van der Windt.;Job Klumper.;Ruben G Duijnhoven.;Marjolein Kok.;Carrie Ris-Stalpers.;Marjon A de Boer.;Anton H van Kaam.;Eva Pajkrt.;Ben W Mol.;Kate F Walker.;Fionnuala M McAuliffe.;Joris A van der Post.;Carolien Roos.;Martijn A Oudijk.; .
来源: Lancet. 2025年405卷10483期1004-1013页
Tocolytics are recommended in international guidelines as treatment for threatened preterm birth. Atosiban, an oxytocin receptor antagonist, is a registered tocolytic drug specifically indicated for the treatment of threatened preterm birth. Although tocolytics have been shown to delay birth, benefits on neonatal outcomes have not been demonstrated. In the APOSTEL 8 trial we aimed to assess superiority of tocolysis with atosiban compared with placebo in threatened preterm birth from 30 weeks and 0 days (30+0 weeks) to 33+6 weeks of gestation in improving neonatal morbidity and mortality.
125. Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials.
作者: Philippe Gevaert.;Martin Desrosiers.;Marjolein Cornet.;Joaquim Mullol.;Eugenio De Corso.;Nesil Keles Turel.;Jorge Maspero.;Shigeharu Fujieda.;Luo Zhang.;Ana R Sousa.;Samantha J Woods.;Angela M Davis.;Stein Schalkwijk.;Dawn Edwards.;Prerna Ranganathan.;Richard Follows.;Carolynne Marshall.;Joseph K Han.; .
来源: Lancet. 2025年405卷10482期911-926页
Chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms are frequently driven by type 2 inflammation. Depemokimab is the first ultra-long-acting biological drug engineered with enhanced interleukin-5 binding affinity, high potency, and an extended half-life, enabling twice per year dosing and sustained type 2 inflammation inhibition. The ANCHOR-1 and ANCHOR-2 trials investigated the efficacy and safety of depemokimab in people with CRSwNP.
126. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial.
作者: Francis Couturaud.;Jeannot Schmidt.;Olivier Sanchez.;Alice Ballerie.;Marie-Antoinette Sevestre.;Nicolas Meneveau.;Laurent Bertoletti.;Jérôme Connault.;Ygal Benhamou.;Joël Constans.;Thomas Quemeneur.;François-Xavier Lapébie.;Gilles Pernod.;Gaël Picart.;Antoine Elias.;Caroline Doutrelon.;Claire Neveux.;Lina Khider.;Pierre-Marie Roy.;Stéphane Zuily.;Nicolas Falvo.;Philippe Lacroix.;Joseph Emmerich.;Isabelle Mahé.;Julien Boileau.;Azzedine Yaici.;Sylvain Le Jeune.;Dominique Stéphan.;Pierre Plissonneau-Duquene.;Valérie Ray.;Marc Danguy des Déserts.;Rafik Belhadj-Chaidi.;Bouchra Lamia.;Yves Gruel.;Emilie Presles.;Philippe Girard.;Cécile Tromeur.;Farès Moustafa.;Vincent Rothstein.;Karine Lacut.;Solen Melac.;Sophie Barillot.;Patrick Mismetti.;Silvy Laporte.;Dominique Mottier.;Guy Meyer.;Christophe Leroyer.; .
来源: Lancet. 2025年405卷10480期725-735页
In patients with venous thromboembolism at high risk of recurrence for whom extended treatment with direct oral anticoagulants has been indicated, the optimal dose is unknown. We aimed to assess efficacy and safety of reduced-dose versus full-dose direct oral anticoagulants in patients in whom extended anticoagulation has been indicated.
127. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial.
作者: Roland Veltkamp.;Eleni Korompoki.;Kirsten H Harvey.;Emily R Harvey.;Cornelia Fießler.;Uwe Malzahn.;Viktoria Rücker.;Joan Montaner.;Valeria Caso.;Igor Sibon.;Peter Ringleb.;Omid Halse.;Klemens Hügen.;Sabine Ullmann.;Carolin Schuhmann.;Gabriele Putz Todd.;Kirsten Haas.;Elena Palà.;Stéphanie Debette.;Morgane Lachaize.;Tim D'Aoust.;Christian Enzinger.;Stefan Ropele.;Simon Fandler-Höfler.;Melanie Haidegger.;Yanzhong Wang.;Hatem A Wafa.;Virginia Cancelloni.;Maria Giulia Mosconi.;Gregory Y H Lip.;Deirdre A Lane.;Walter E Haefeli.;Kathrin I Foerster.;Viktoria S Wurmbach.;Peter Brønnum Nielsen.;Karim Hajjar.;Patrick Müller.;Sven Poli.;Jan Purrucker.;Mona Laible.;Lucio D'Anna.;Yolanda Silva.;Reyes de Torres Chacon.;Patricia Martínez-Sánchez.;Marion Boulanger.;Bo Norrving.;Guillaume Paré.;Rolf Wachter.;George Ntaios.;Charles D A Wolfe.;Peter U Heuschmann.; .
来源: Lancet. 2025年405卷10482期927-936页
Direct oral anticoagulants (DOACs) reduce the rate of thromboembolism in patients with atrial fibrillation but the benefits and risks in survivors of intracerebral haemorrhage are uncertain. We aimed to determine whether DOACs reduce the risk of ischaemic stroke without substantially increasing the risk of recurrent intracerebral haemorrhage.
128. Efficacy and safety of intravenous nerinetide initiated by paramedics in the field for acute cerebral ischaemia within 3 h of symptom onset (FRONTIER): a phase 2, multicentre, randomised, double-blind, placebo-controlled study.
作者: Jim Christenson.;Michael D Hill.;Richard H Swartz.;Corey Adams.;Oscar Benavente.;Leanne K Casaubon.;Sheldon Cheskes.;Aravind Ganesh.;Jonathan Dave Garman.;Cameron Harris.;Devin R Harris.;Kathy Heard.;Sandra Jenneson.;Yatika Kohli.;Michelle Leroux.;Diana Mayor-Nunez.;George Medvedev.;Manu Mehdiratta.;Laurie J Morrison.;Johanna Maria Ospel.;Sarah Pennington.;Yael Perez.;Daniel Selchen.;Alexander Stebner.;John Tallon.;Aleksander Tkach.;Pieter Richard Verbeek.;Michael Tymianski.
来源: Lancet. 2025年405卷10478期571-582页
Nerinetide is a neuroprotectant effective in preclinical models of acute ischaemic stroke when administered within 3 h of onset. However, the clinical evaluation of neuroprotectants in this short timeframe is challenging. We sought to establish the feasibility, safety, and effectiveness of nerinetide when given before hospital arrival within 3 h of symptom onset of suspected stroke.
129. Efficacy and safety of nerinetide in acute ischaemic stroke in patients undergoing endovascular thrombectomy without previous thrombolysis (ESCAPE-NEXT): a multicentre, double-blind, randomised controlled trial.
作者: Michael D Hill.;Mayank Goyal.;Andrew M Demchuk.;Bijoy K Menon.;Thalia S Field.;William C Guest.;Jorg Berrouschot.;Albrecht Bormann.;Mirko Pham.;Karl G Haeusler.;Diedrick W J Dippel.;Pieter J van Doormaal.;Franziska Dorn.;Felix J Bode.;Brian A van Adel.;Demetrios J Sahlas.;Richard H Swartz.;Leodante Da Costa.;Johanna M Ospel.;Rosalie V McDonough.;Karla J Ryckborst.;Mohammed A Almekhlafi.;Kathy J Heard.;David J Garman.;Corey Adams.;Yatika Kohli.;Bridget A Schoon.;Brian H Buck.;Mario Muto.;Atif Zafar.;Hauke Schneider.;Jonathan A Grossberg.;Leonard L L Yeo.;Jason W Tarpley.;Marios-Nikos Psychogios.;Jonathan M Coutinho.;Nicola Limbucci.;Volker Puetz.;Michael E Kelly.;Bruce C V Campbell.;Sven Poli.;Alexandre Y Poppe.;Jai J Shankar.;Ronil Chandra.;Dar Dowlatshahi.;George A Lopez.;Luigi Cirillo.;Aimen Moussaddy.;Michael Devlin.;Pablo Garcia-Bermejo.;Jennifer L Mandzia.;Mona Skjelland.;Anne Hege Aamodt.;Frank L Silver.;Timothy J Kleinig.;Guglielmo Pero.;Jens Minnerup.;Ryan A McTaggart.;Ajit S Puri.;Albert H Y Chiu.;Gernot Reimann.;Gordon J Gubitz.;Marie-Christine Camden.;Seon Kyu Lee.;Eric Sauvageau.;Sibu Mundiyanapurath.;Donald F Frei.;Hana Choe.;Marcello Rocha.;Jan Gralla.;Peter Bailey.;Sebastian Fischer.;Thomas Liebig.;Konstantin Dimitriadis.;Dheeraj Gandhi.;René Chapot.;Albert Jin.;Ameer E Hassan.;Wim van Zwam.;Ilko L Maier.;Martin Wiesmann.;Wolf-Dirk Niesen.;Rajiv Advani.;Agnethe Eltoft.;Negar Asdaghi.;Cynthia Murphy.;Luca Remonda.;Darshan Ghia.;Olav Jansen.;Markus Holtmannspoetter.;Victoria Hellstern.;Karsten Witt.;Annette Fromme.;Shahid M Nimjee.;David Turkel-Parella.;Dominik Michalski.;Christian Maegerlein.;Carol Huilian Tham.;Michael Tymianski.; .
来源: Lancet. 2025年405卷10478期560-570页
In the ESCAPE-NA1 trial, treatment with nerinetide, an eicosapeptide that interferes with post-synaptic density protein 95, was associated with improved functional outcome among patients with acute ischaemic stroke due to large vessel occlusion undergoing endovascular thrombectomy without co-treatment with an intravenous thrombolytic agent. There was no benefit when intravenous thrombolytic agent co-treatment was used. We sought to confirm the clinical benefit of nerinetide in the absence of previous intravenous thrombolytic drug treatment.
130. Normobaric hyperoxia combined with endovascular treatment for acute ischaemic stroke in China (OPENS-2 trial): a multicentre, randomised, single-blind, sham-controlled trial.
作者: Weili Li.;Jing Lan.;Ming Wei.;Lan Liu.;Chengbei Hou.;Zhifeng Qi.;Chuanhui Li.;Liqun Jiao.;Qi Yang.;Wenhuo Chen.;Shuling Liu.;Xincan Yue.;Qinglin Dong.;Haicheng Yuan.;Zongen Gao.;Xiangbin Wu.;Changming Wen.;Tong Li.;Changchun Jiang.;Di Li.;Zuoquan Chen.;Junfeng Shi.;Wanchao Shi.;Jinglin Yuan.;Yijie Qin.;Binglong Li.;Marc Fisher.;Wuwei Feng.;Ke Jian Liu.;Xunming Ji.; .
来源: Lancet. 2025年405卷10477期486-497页
Endovascular treatment improves the recanalisation rate for patients with acute ischaemic stroke; however, even with endovascular treatment, approximately half of patients do not have a favourable functional outcome. We aimed to evaluate the effect of normobaric hyperoxia combined with endovascular treatment on functional outcomes up to 90 days after treatment in patients who had an acute ischaemic stroke with large-vessel occlusion.
131. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial.
作者: Nirosen Vijiaratnam.;Christine Girges.;Grace Auld.;Rachel McComish.;Alexa King.;Simon S Skene.;Steve Hibbert.;Alan Wong.;Sabina Melander.;Rachel Gibson.;Helen Matthews.;John Dickson.;Camille Carroll.;Abigail Patrick.;Jemma Inches.;Monty Silverdale.;Bethan Blackledge.;Jessica Whiston.;Michele Hu.;Jessica Welch.;Gordon Duncan.;Katie Power.;Sarah Gallen.;Jacqueline Kerr.;K Ray Chaudhuri.;Lucia Batzu.;Silvia Rota.;Edwin Jabbari.;Huw Morris.;Patricia Limousin.;Nigel Greig.;Yazhou Li.;Vincenzo Libri.;Sonia Gandhi.;Dilan Athauda.;Kashfia Chowdhury.;Tom Foltynie.
来源: Lancet. 2025年405卷10479期627-636页
GLP-1 receptor agonists have neurotrophic properties in in-vitro and in-vivo models of Parkinson's disease and results of epidemiological studies and small randomised trials have suggested possible benefits for risk and progression of Parkinson's disease. We aimed to establish whether the GLP-1 receptor agonist, exenatide, could slow the rate of progression of Parkinson's disease.
132. Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
作者: Janet A Dunn.;Peter Donnelly.;Nada Elbeltagi.;Andrea Marshall.;Amy Hopkins.;Alastair M Thompson.;Riccardo Audisio.;Sarah E Pinder.;David A Cameron.;Sue Hartup.;Lesley Turner.;Annie Young.;Helen Higgins.;Eila K Watson.;Sophie Gasson.;Peter J Barrett-Lee.;Claire Hulme.;Bethany Shinkins.;Peter S Hall.;Andrew Evans.
来源: Lancet. 2025年405卷10476期396-407页
The frequency of mammographic surveillance for women after diagnosis of breast cancer varies globally. The aim of this study was to evaluate whether less than annual mammography was non-inferior in terms of breast cancer-specific survival in women aged 50 years or older.
133. Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.
作者: Thierry André.;Elena Elez.;Heinz-Josef Lenz.;Lars Henrik Jensen.;Yann Touchefeu.;Eric Van Cutsem.;Rocio Garcia-Carbonero.;David Tougeron.;Guillermo Ariel Mendez.;Michael Schenker.;Christelle de la Fouchardiere.;Maria Luisa Limon.;Takayuki Yoshino.;Jin Li.;Jose Luis Manzano Mozo.;Laetitia Dahan.;Giampaolo Tortora.;Myriam Chalabi.;Eray Goekkurt.;Maria Ignez Braghiroli.;Rohit Joshi.;Timucin Cil.;Francine Aubin.;Elvis Cela.;Tian Chen.;Ming Lei.;Lixian Jin.;Steven I Blum.;Sara Lonardi.
来源: Lancet. 2025年405卷10476期383-395页
CheckMate 8HW prespecified dual primary endpoints, assessed in patients with centrally confirmed microsatellite instability-high or mismatch repair-deficient status: progression-free survival with nivolumab plus ipilimumab compared with chemotherapy as first-line therapy and progression-free survival with nivolumab plus ipilimumab compared with nivolumab alone, regardless of previous systemic treatment for metastatic disease. In our previous report, nivolumab plus ipilimumab showed superior progression-free survival versus chemotherapy in first-line microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer in the CheckMate 8HW trial. Here, we report results from the prespecified interim analysis for the other primary endpoint of progression-free survival for nivolumab plus ipilimumab versus nivolumab across all treatment lines.
134. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
作者: Michelle C Williams.;Ryan Wereski.;Christopher Tuck.;Philip D Adamson.;Anoop S V Shah.;Edwin J R van Beek.;Giles Roditi.;Colin Berry.;Nicholas Boon.;Marcus Flather.;Steff Lewis.;John Norrie.;Adam D Timmis.;Nicholas L Mills.;Marc R Dweck.;David E Newby.; .
来源: Lancet. 2025年405卷10475期329-337页
The Scottish Computed Tomography of the Heart (SCOT-HEART) trial demonstrated that management guided by coronary CT angiography (CCTA) improved the diagnosis, management, and outcome of patients with stable chest pain. We aimed to assess whether CCTA-guided care results in sustained long-term improvements in management and outcomes.
135. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial.
作者: Nisha R Acharya.;Athimalaipet V Ramanan.;Alison B Coyne.;Kathryn L Dudum.;Elia M Rubio.;Sydney M Woods.;Catherine M Guly.;Elena Moraitis.;Harry J D Petrushkin.;Kate Armon.;Narman Puvanachandra.;Jessy T Choi.;Daniel P Hawley.;Benjamin F Arnold.; .
来源: Lancet. 2025年405卷10475期303-313页
Adalimumab is an effective treatment for juvenile idiopathic arthritis-associated uveitis. Data are scarce on the effects of discontinuing adalimumab after control of the disease had been reached. We aimed to assess efficacy and safety of discontinuing treatment in patients with juvenile idiopathic arthritis-associated uveitis.
136. Appendicectomy versus antibiotics for acute uncomplicated appendicitis in children: an open-label, international, multicentre, randomised, non-inferiority trial.
作者: Shawn D St Peter.;Janelle R Noel-MacDonnell.;Nigel J Hall.;Simon Eaton.;Janne S Suominen.;Tomas Wester.;Jan F Svensson.;Markus Almström.;E Pete Muenks.;Marianne Beaudin.;Nelson Piché.;Mary Brindle.;Ali MacRobie.;Richard Keijzer.;Helene Engstrand Lilja.;Ann-Marie Kassa.;Tim Jancelewicz.;Andreana Butter.;Jacob Davidson.;Erik Skarsgard.;Yap Te-Lu.;Shireen Nah.;Andrew R Willan.;Agostino Pierro.
来源: Lancet. 2025年405卷10474期233-240页
Support for the treatment of uncomplicated appendicitis with non-operative management rather than surgery has been increasing in the literature. We aimed to investigate whether treatment of uncomplicated appendicitis with antibiotics in children is inferior to appendicectomy by comparing failure rates for the two treatments.
137. Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
作者: David Fiorentino.;Aaron R Mangold.;Victoria P Werth.;Lisa Christopher-Stine.;Alisa Femia.;Myron Chu.;Amy C M Musiek.;Jason C Sluzevich.;Lauren V Graham.;Anthony P Fernandez.;Rohit Aggarwal.;Kerri Rieger.;Karen M Page.;Xingpeng Li.;Craig Hyde.;Natalie Rath.;Abigail Sloan.;Barry Oemar.;Anindita Banerjee.;Mikhail Salganik.;Christopher Banfield.;Srividya Neelakantan.;Jean S Beebe.;Michael S Vincent.;Elena Peeva.;Ruth Ann Vleugels.
来源: Lancet. 2025年405卷10473期137-146页
Dermatomyositis is a chronic autoimmune disease with distinctive cutaneous eruptions and muscle weakness, and the pathophysiology is characterised by type I interferon (IFN) dysregulation. This study aims to assess the efficacy, safety, and target engagement of dazukibart, a potent, selective, humanised IgG1 neutralising monoclonal antibody directed against IFNβ, in adults with moderate-to-severe dermatomyositis.
138. Durvalumab with or without bevacizumab with transarterial chemoembolisation in hepatocellular carcinoma (EMERALD-1): a multiregional, randomised, double-blind, placebo-controlled, phase 3 study.
作者: Bruno Sangro.;Masatoshi Kudo.;Joseph P Erinjeri.;Shukui Qin.;Zhenggang Ren.;Stephen L Chan.;Yasuaki Arai.;Jeong Heo.;Anh Mai.;Jose Escobar.;Yamil Alonso Lopez Chuken.;Jung-Hwan Yoon.;Won Young Tak.;Valeriy V Breder.;Tanita Suttichaimongkol.;Mohamed Bouattour.;Shi-Ming Lin.;Jean-Marie Peron.;Quang T Nguyen.;Lunan Yan.;Chang-Fang Chiu.;Florinda A Santos.;Anil Veluvolu.;Satheesh Chiradoni Thungappa.;Marco Matos.;Magdalena Żotkiewicz.;Stephanie I Udoye.;John F Kurland.;Gordon J Cohen.;Riccardo Lencioni.; .
来源: Lancet. 2025年405卷10474期216-232页
Transarterial chemoembolisation (TACE) is standard of care for patients with unresectable hepatocellular carcinoma that is amenable to embolisation; however, median progression-free survival is still approximately 7 months. We aimed to assess whether adding durvalumab, with or without bevacizumab, might improve progression-free survival.
139. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study.
作者: Masatoshi Kudo.;Zhenggang Ren.;Yabing Guo.;Guohong Han.;Hailan Lin.;Jinfang Zheng.;Sadahisa Ogasawara.;Ji Hoon Kim.;Haitao Zhao.;Chuan Li.;David C Madoff.;R Mark Ghobrial.;Tomokazu Kawaoka.;René Gerolami.;Masafumi Ikeda.;Hiromitsu Kumada.;Anthony B El-Khoueiry.;Arndt Vogel.;Xiang Peng.;Kalgi Mody.;Corina Dutcus.;Leonid Dubrovsky.;Abby B Siegel.;Richard S Finn.;Josep M Llovet.; .
来源: Lancet. 2025年405卷10474期203-215页
Transarterial chemoembolisation (TACE) is standard care for unresectable, non-metastatic hepatocellular carcinoma. We aimed to evaluate the addition of lenvatinib and pembrolizumab to TACE versus dual placebo plus TACE in patients with unresectable, non-metastatic hepatocellular carcinoma.
140. Effect of a spatial repellent on malaria incidence in an area of western Kenya characterised by high malaria transmission, insecticide resistance, and universal coverage of insecticide treated nets (part of the AEGIS Consortium): a cluster-randomised, controlled trial.
作者: Eric O Ochomo.;John E Gimnig.;Quentin Awori.;Bernard Abong'o.;Prisca Oria.;Nickline K Ashitiba.;Brian Polo.;Vincent Moshi.;Hilda Otanga.;Ferdinard Adung'o.;Eunice A Ouma.;Susan Outa.;Edith Ramaita.;Rebecca Levine.;Wycliffe Odongo.;Steven A Harvey.;April Monroe.;Ashley Hudson.;Bradley Sandberg.;Jared Hendrickson.;Xingyuan Zhao.;Ruyu Zhou.;Fang Liu.;Nicole L Achee.;John P Grieco.
来源: Lancet. 2025年405卷10473期147-156页
Spatial repellent products are used for prevention of insect bites, and a body of evidence exists on spatial repellent entomological efficacy. A new option for vector control, spatial repellent products are designed to release active ingredient into the air for disruption of human-vector contact thereby reducing human exposure to mosquito-borne pathogens. Clinical trials have shown spatial repellent epidemiological efficacy against Aedes-borne viruses but inconclusive outcomes against malaria. We aimed to show and quantify the protective efficacy of spatial repellents in reducing malaria infection incidence in Busia County, Kenya.
|